Axsome Therapeutics (AXSM) reported $150.04 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 72.1$0.92 for the same period compares to -$1.24 a year ago. The reported revenue compares to the Zacks Consensus Estimate of$139.61 million, representing a surprise of +7.47%. The company delivered an EPS surprise of +8%, with the consensus EPS estimate being -$1.00. Shares of Axsome have returned -2.3% over the past month versus the Zacks S&P 500 composite's ...